FDA supplemental approval: Lidocaine Hydrochloride (Labeling)

AI Summary

This record documents an FDA supplemental approval for labeling changes to lidocaine hydrochloride 2% injectable injection (ANDA 040078, sponsor Hospira), approved 5 June 2026. The record itself contains no clinical trial data, efficacy information, or safety outcomes; it is a regulatory administrative action only.

Plain-language summary

This is an FDA supplemental approval action for labeling changes to an already-approved injectable lidocaine product; it documents a regulatory decision, not clinical trial evidence.

Reported figures

Quoted from the source exactly as published.

Caveats

• This is a regulatory action record only; no clinical trial results, efficacy data, safety outcomes, or specific labeling changes are described in the source.
• The nature, scope, or rationale for the labeling supplement is not stated in this record.
• No study population, sample size, endpoints, or comparative analysis are available.
• This approval action does not indicate new clinical evidence or a change in the clinical evidence base; it documents an administrative decision by FDA.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.